Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A prospective, randomized, controlled multicenter trial to evaluate 1.25 mmol/L
(physiological) vs. 1.5 mmol/L calcium dialysate on serum markers of mineral metabolism,
secondary hyperparathyroidism and cardiovascular calcification in prevalent haemodialysis
patients. And the long term safety of the 1.25 mmol/L calcium dialysate was also considered.
There are two phases of study for each subject. Phase 1 (screening phase). During this phase,
each potential subject will be evaluated to determine if he/she is eligible for the study.
Phase 2 (intervention phase). Each subject will be randomly allocated to physiological
calcium dialysate (1.25 mmol/L calcium dialysate) group (PCD group), and normal calcium
dialysate (1.5 mmol/L calcium dialysate) group (NCD group). The follow-up duration was 36
months.